Mosaic ImmunoEngineering (OTCMKTS:CPMV – Get Free Report) released its quarterly earnings results on Wednesday. The company reported ($0.02) EPS for the quarter, Zacks reports.
Mosaic ImmunoEngineering Stock Performance
CPMV opened at $0.69 on Thursday. The firm has a market cap of $5.03 million, a P/E ratio of -6.95 and a beta of -0.68. Mosaic ImmunoEngineering has a 12 month low of $0.25 and a 12 month high of $1.05. The stock has a 50-day moving average of $0.66 and a 200 day moving average of $0.58.
Mosaic ImmunoEngineering Company Profile
Mosaic ImmunoEngineering (OTCMKTS:CPMV) is a development-stage biotechnology company focused on advancing immunotherapies and vaccine candidates through its proprietary nanoparticle platform. The company leverages virus-like particles derived from the cowpea mosaic virus (CPMV) to serve as both antigen carriers and immune stimulators, aiming to enhance the magnitude and durability of immune responses. By engineering these plant-based VLPs to display target antigens or adjuvant properties, Mosaic ImmunoEngineering seeks to create differentiated candidates for oncology indications and infectious disease prevention.
Operating out of the United States, Mosaic ImmunoEngineering is currently in preclinical stages of development.
Read More
- Five stocks we like better than Mosaic ImmunoEngineering
- TJX Companies Fires on All Cylinders With 9% Revenue Growth
- From Zepbound to Foundayo: Lilly’s Latest Results Support Oral GLP-1 Outlook
- AI Consolidation Begins: Blackstone & Google Forge an AI Empire
- USA Rare Earth Posts Strong Q1 2026 as Massive Serra Vera Deal Looms
Receive News & Ratings for Mosaic ImmunoEngineering Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mosaic ImmunoEngineering and related companies with MarketBeat.com's FREE daily email newsletter.
